Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma

Autor: Sarfraz Memon, Moreno, M. B., Petrak, D., Zacharchuk, C. M.

Publikováno v: Scopus-Elsevier

Overexpression of Bcl-2 can prevent or markedly delay cell death induced by a variety of apoptotic stimuli. Although Fas and Fas ligand (FasL) interactions play a major role in the elimination of self-reactive T cells in the periphery, inhibition of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df7c045555d2344a54ef7e4c66059d02
https://doi.org/10.4049/jimmunol.155.10.4644

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.

Autor: Pegram MD; Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, 900 Blake Wilbur, Stanford, CA, 94305, USA., Bondarenko I; Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, 31 Blyzhnya Street, Dnipro, 49102, Ukraine., Zorzetto MMC; Department of Clinical Oncology, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331 - Dr. Paulo Prata, Barretos, São Paulo, 14784-400, Brazil., Hingmire S; Department of Oncology, Deenanath Mangeshkar Hospital and Research Centre, Erandawne, Pune, Maharashtra, 411004, India., Iwase H; Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Science, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan., Krivorotko PV; Department of Breast Tumors, Petrov Research Institute of Oncology, 68 Leningradskaya Street, Pesochny, 197758, Saint Petersburg, Russian Federation., Lee KS; Center for Breast Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea., Li RK; Section of Medical Oncology, Cancer Institute, St. Luke's Medical Center, 279 E Rodriguez Sr. Ave, Quezon City, 1112, Metro Manila, Philippines., Pikiel J; Copernicus, Wojewódzkie Centrum Onkologii, Al. Zwycięstwa 31/32, 80-210, Gdańsk, Poland., Aggarwal R; Pfizer Essential Health, Worldwide Safety, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA., Ewesuedo R; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA. reginald.ewesuedo@pfizer.com., Freyman A; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA., Li R; Early Clinical Development Statistics, Pfizer Inc, 1 Portland Street, Cambridge, MA, 02139, USA., Vana A; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA., Yin D; Clinical Pharmacology, Pfizer Inc, 10777 Science Center Drive, San Diego, CA, 92121, USA., Zacharchuk C; Pfizer Essential Health, Biosimilars Clinical R&D, Pfizer Inc, 610 Main Street, Cambridge, MA, 02139, USA., Tan-Chiu E; Medical Oncology, Florida Cancer Research Institute, 201 NW 82nd Avenue, Suite 102, Plantation, FL, 33324, USA.

Publikováno v: British journal of cancer [Br J Cancer] 2019 Jan; Vol. 120 (2), pp. 172-182. Date of Electronic Publication: 2018 Dec 20.

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.

Autor: Jacobs I; Pfizer Inc, Pfizer Essential Health, 235 East 42nd Street, New York, NY, 10017-5755, USA. ira.jacobs@pfizer.com., Ewesuedo R; Pfizer Inc, Biosimilars Development, Cambridge, MA, USA., Lula S; Envision Pharma Group, London, UK., Zacharchuk C; Pfizer Inc, Biosimilars Development, Cambridge, MA, USA.

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2017 Feb; Vol. 31 (1), pp. 1-36.

Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3-d]pyrimidine derivatives as new EGFR inhibitors.

Autor: Sobh, Eman A.¹ (AUTHOR) Eman_abd-elfattah@phrm.menofia.edu.eg, Dahab, Mohammed A.² (AUTHOR) mohammeddahab@azhar.edu.eg, Elkaeed, Eslam B.³ (AUTHOR), Alsfouk, Aisha A.⁴ (AUTHOR), Ibrahim, Ibrahim M.⁵ (AUTHOR), Metwaly, Ahmed M.^6,7 (AUTHOR), Eissa, Ibrahim H.² (AUTHOR) Ibrahimeissa@azhar.edu.eg

Publikováno v: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-21. 21p.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Autor: Moy B; Massachusetts General Hospital, Boston Massachusetts, USA;, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I

Publikováno v: The oncologist [Oncologist] 2014 Apr; Vol. 19 (4), pp. 348-9. Date of Electronic Publication: 2014 Mar 27.